Navigation Links
CRi to Distribute VisEn Medical's Portfolio of Fluorescence In Vivo Imaging Agents and Labels in North America
Date:1/20/2009

Distribution Partnership Expands Industry Adoption and Standardization of Leading Fluorescence Agents and Imaging Applications

BEDFORD, Mass., Jan. 20 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc (CRi) and VisEn Medical announced today that they have signed a non-exclusive agreement to enable CRi to distribute VisEn's proprietary portfolio of fluorescent imaging agents and labels in North America. The distribution partnership is designed to broaden and extend today's leading fluorescence in vivo imaging technologies, applications and standards in research and drug development.

"With a deep heritage in multi-spectral fluorescence in vivo imaging and fluorescence microscopy imaging systems, we have built a significant customer base with a broad range of applications in life science research today. Bringing VisEn's fluorescent in vivo agents and labels to our Maestro(TM) multispectral fluorescence imaging system customers now expands the breadth of research for them, and for CRi," said George Abe, CRi's President and CEO. "We are pleased to be partnering with VisEn around their unparalleled agent products, and we look forward to continually expanding today's areas of in vivo research together."

VisEn's proprietary in vivo imaging agents and labels are designed to provide a robust and broad range of biologically-specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways in vivo, with several more new agents expected for launch in 2009. Key research areas enabled by the VisEn agents include imaging disease progression and therapeutic response in real time in oncology, inflammation, cardiovascular disease, bone disease, and pulmonary diseases, all in the context of the living animal. VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag(R) fluorescence labeling dyes for custom in vivo agent development, and its NanoSpark(R) in vivo labeling nanoparticles, all designed and optimized specifically for superior brightness, biocompatibility, stability and results in in vivo imaging. VisEn's agents and labels are designed to be compatible with a range of fluorescence imaging systems, including the CRi Maestro(TM) system with its powerful proprietary multispectral imaging technology. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

"We are pleased to be working with CRi to further extend the applications and markets for our collective suite of fluorescence imaging technologies," said Kirtland Poss, President and CEO of VisEn Medical. "With several applications already developed in oncology and inflammation using the VisEn agents on the Maestro platforms, we look forward to working with CRi in rapidly expanding today's research areas in fluorescence imaging in vivo."

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.

About CRi

Cambridge Research & Instrumentation, Inc (CRi) is a Boston-based biomedical imaging company providing innovative optical imaging solutions for more than 20 years. CRi's multidisciplinary team is dedicated to providing comprehensive solutions that enable our customers to produce breakthroughs in research and medical care. CRi technology helps extract new disease-specific information from biological and clinical samples in the physiological, morphological, and biochemical context of intact tissues and organisms.

With over 80 patents pending and issued, CRi's award-winning innovations are being utilized around the world in a wide range of settings, ranging from academic researcher to pharmaceutical drug development to clinical medicine. CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-art manufacturing facility. We are able to rapidly design and manufacture system-level solutions for a variety of growing market applications.

Learn more at www.cri-inc.com.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Angel Food Ministries to Distribute Holiday Grocery Relief
2. TEAC Forms Strategic Alliance With SST Group, Inc. to Distribute Its Next Generation Medical Disc Publishing Systems Into Medical Market
3. Greene & Phillips to Distribute Complimentary Hands-Free Headsets
4. Prasco to Distribute Generic Forms of Dorzolamide Hydrochloride-Timolol Maleate and Dorzolamide Hydrochloride Ophthalmic Solutions (Comparable to Mercks COSOPT(R) and TRUSOPT(R) Ophthalmic Solutions)
5. DRE Veterinary Distributes All-In-One Veterinary Dental Cart
6. China Medicine Maintains Exclusive Rights to Distribute 2,300 Pharmaceutical Products
7. Free Wheelchair Mission to Distribute 4,400 Wheelchairs to China Earthquake Victims
8. Whatman, Now Part of GE Healthcare, to Distribute GenVault DNA Recovery Kits in North America
9. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
10. Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities
11. 20 Million Kids Books Distributed, 25% of U.S. Children in Poverty Getting Books, 50,000 Doctors Trained: Three Key Milestones for Reach Out and Read
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
Breaking Medicine Technology: